Brainsway Ltd. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Jerusalem, IL. In its latest annual figures on file, for the fiscal year ended 2024-12-31, it reported revenue of $41 million and a profit of $3 million (its filed statements).
Product businessSurgical & Medical Instruments & ApparatusJerusalem, ILfilings since 20118 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.2 out of ten, 8 of 9 metrics filed and 1 estimated: past 5.7 out of ten, present 5.7 out of ten, future 7.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2017. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.2 out of ten. +20.5% a year over 8 filed years; profitable in 1 of 8. 51st percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.2 out of ten. Share count grew 2.9% a year. 0% of cash flow returned. Insiders: 7 sales, 0 purchases. 32nd percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 6.3 out of ten. ROE 5%: 5¢ of profit per shareholder dollar. Leverage 34%: owes 34¢ per asset dollar. 63rd percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.3 out of ten. top 47% of 109 in its family; net margin 7.1%. 53rd percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 105 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 8.1 out of ten. top 19% of 104 in its family for room to expand. 81st percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.2 out of ten. top 48% of 105 in its family for growth drivers. 52nd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.6 out of ten. top 14% of 88 in its family for expectations against reality. 86th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-04-20 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-29. Filings on record since 2011. Read from EDGAR 2026-10-12.
Who runs it
Levy, Hadar (Chief Executive Officer); Marom, Ido (Chief Financial Officer); Moiseyev, Gilad (Chief Technology Officer); Roth, Yiftach (Chief Scientist); Rozenfeld, Naomi (Chief Marketing Officer); Hanlon, Colleen (VP of Medical Affairs); Mitrany, Rayten Michal Ety (director); Boehm, Amiram (director); Lushi, Avner (director); Sarid, Karen (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.